February 1, 2017 The Nine-Hole Peg Test as a Manual Dexterity Performance Measure for Multiple Sclerosis
February 1, 2017 Validity of the Timed 25-Foot Walk as an Ambulatory Performance Outcome Measure for Multiple Sclerosis
February 1, 2017 A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease
February 1, 2017 Validity of the Symbol Digit Modalities Test as a Cognition Performance Outcome Measure for Multiple Sclerosis
January 31, 2017 Accelerating drug development for Alzheimer’s disease through the use of data standards
January 31, 2017 Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team
January 31, 2017 Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients
January 31, 2017 Highlights from the 02 August CDISC Strategy Session The CDISC Strategy Session highlight video includes an interview with Cheryl Fitzer-Attas (CHDI Foundation) discussing the importa
January 17, 2017 ReSeqTB Data Platform Now Available to Public January 17, 2017 TUCSON, Ariz., January 17, 2017 —The Rapid Drug Susceptibility Testing Consortium, coordinated by
January 12, 2017 A Standardised Method for Interpreting the Association Between Mutations and Phenotypic Drug Resistance in Mycobacterium Tuberculosis
